• MiNK Therapeutics’ third-quarter 2026 net loss per share narrowed 23% year over year to $0.50.
• First pre-commercial product revenue reached $200,000 from agenT-797 named-patient access; quarter-end cash and cash equivalents totaled $7.47 million.
• General and administrative expense fell 44% year over year to $1 million, primarily due to lower professional fees and stock compensation expense.
• The randomized Phase 2 ARDS trial continued enrolling, with U.S. dosing expected before year-end 2026 and comparative data in second-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110730PRIMZONEFULLFEED9875360) on November 11, 2026, and is solely responsible for the information contained therein.